MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • ADVENTRX Pharmaceuticals, Inc. Officially Changes Name To Mast Therapeutics, Inc. (MSTX) 0 comments
    Mar 11, 2013 5:53 PM

    San Diego-based biopharmaceutical company ADVENTRX Pharmaceuticals announced today that its previously announced corporate name change has now gone into effect. The company's name has now officially been changed to "Mast Therapeutics, Inc." Effective at the opening of trading today, the company's new ticker symbol is "MSTX." Mast Therapeutics' stock is listed on the NYSE MKT.

    Mast Therapeutics' lead product candidate will be hereafter referred to as "MST-188" (formerly ANX-188). Additionally, a new CUSIP number, 576314 108, has been assigned to the company's common stock.

    Outstanding stock certificates and warrants for shares of the company's common stock have not been affected by the name change, and they will continue to be valid and do not need to be exchanged.

    Mast Therapeutics is a publicly traded biopharmaceutical company engaged in leveraging its MAST (Molecular Adhesion and Sealant Technology) platform - which has resulted from more than 20 years of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers - in the development of MST-188, the company's lead product candidate. MST-188 has been created to address serious or life-threatening diseases of significant unmet need and is a cytoprotective, hemorheologic, anti-inflammatory, and anti-thrombotic agent with potential utility in diseases or conditions that are characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow). Mast Therapeutics is headquartered in San Diego, Calif.

    Mast Therapeutics is currently recruiting subjects in EPIC, its pivotal Phase 3 study of MST-188 in sickle cell disease. A Phase 2 clinical study of MST-188 in acute limb ischemia - a complication of peripheral arterial disease - is planned for late 2013 or early 2014.

    For more information, visit www.masttherapeutics.com

    Sign up for "The Mission Report" at www.MissionIR.com

Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.